The plasminogen activating system in the pathogenesis of Alzheimer's disease.

Alzheimer’s disease amyloid precursor protein amyloid β neuroserpin plasmin plasminogen activating system plasminogen activator inhibitor-1 synapse tissue-type plasminogen activator urokinase-type plasminogen activator

Journal

Neural regeneration research
ISSN: 1673-5374
Titre abrégé: Neural Regen Res
Pays: India
ID NLM: 101316351

Informations de publication

Date de publication:
Oct 2021
Historique:
entrez: 1 3 2021
pubmed: 2 3 2021
medline: 2 3 2021
Statut: ppublish

Résumé

Dementia is a clinical syndrome that affects approximately 47 million people worldwide and is characterized by progressive and irreversible decline of cognitive, behavioral and sesorimotor functions. Alzheimer's disease (AD) accounts for approximately 60-80% of all cases of dementia, and neuropathologically is characterized by extracellular deposits of insoluble amyloid-β (Aβ) and intracellular aggregates of hyperphosphorylated tau. Significantly, although for a long time it was believed that the extracellular accumulation of Aβ was the culprit of the symptoms observed in these patients, more recent studies have shown that cognitive decline in people suffering this disease is associated with soluble Aβ-induced synaptic dysfunction instead of the formation of insoluble Aβ-containing extracellular plaques. These observations are translationally relevant because soluble Aβ-induced synaptic dysfunction is an early event in AD that precedes neuronal death, and thus is amenable to therapeutic interventions to prevent cognitive decline before the progression to irreversible brain damage. The plasminogen activating (PA) system is an enzymatic cascade that triggers the degradation of fibrin by catalyzing the conversion of plasminogen into plasmin via two serine proteinases: tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Experimental evidence reported over the last three decades has shown that tPA and uPA play a role in the pathogenesis of AD. However, these studies have focused on the ability of these plasminogen activators to trigger plasmin-induced cleavage of insoluble Aβ-containing extracellular plaques. In contrast, recent evidence indicates that activity-dependent release of uPA from the presynaptic terminal of cerebral cortical neurons protects the synapse from the deleterious effects of soluble Aβ via a mechanism that does not require plasmin generation or the cleavage of Aβ fibrils. Below we discuss the role of the PA system in the pathogenesis of AD and the translational relevance of data published to this date.

Identifiants

pubmed: 33642369
pii: NeuralRegenRes_2021_16_10_1973_308076
doi: 10.4103/1673-5374.308076
pmc: PMC8343336
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1973-1977

Subventions

Organisme : BLRD VA
ID : I01 BX003441
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS091201
Pays : United States

Déclaration de conflit d'intérêts

None

Références

Semin Cell Dev Biol. 2017 Feb;62:152-159
pubmed: 27639894
Nat Rev Genet. 2002 Oct;3(10):759-68
pubmed: 12360234
J Clin Invest. 1993 Aug;92(2):679-85
pubmed: 8349806
Blood. 2000 Jul 15;96(2):569-76
pubmed: 10887120
J Neurosci. 2000 Jun 1;20(11):3937-46
pubmed: 10818128
EMBO Rep. 2000 Dec;1(6):530-5
pubmed: 11263499
BMC Neurol. 2017 Nov 7;17(1):196
pubmed: 29115923
EMBO J. 1996 Jun 17;15(12):2944-53
pubmed: 8670795
Biochem J. 2000 Feb 1;345 Pt 3:595-601
pubmed: 10642518
Ann Neurol. 1991 Oct;30(4):572-80
pubmed: 1789684
Pflugers Arch. 2017 Nov;469(11):1415-1423
pubmed: 28656379
Ann Neurol. 1999 Mar;45(3):358-68
pubmed: 10072051
Mol Brain. 2015 Nov 09;8(1):73
pubmed: 26552445
Lancet Neurol. 2019 Jan;18(1):88-106
pubmed: 30497964
Science. 2002 Oct 25;298(5594):789-91
pubmed: 12399581
J Neurosci. 2017 Oct 25;37(43):10310-10322
pubmed: 28931568
Nat Med. 1995 Feb;1(2):138-42
pubmed: 7585010
J Biol Chem. 2017 Feb 17;292(7):2741-2753
pubmed: 27986809
Front Neurosci. 2019 Jul 23;13:735
pubmed: 31396031
Eur J Neurosci. 1993 Jun 1;5(6):633-47
pubmed: 8261137
PLoS One. 2015 Apr 13;10(4):e0123932
pubmed: 25874935
Science. 1995 Dec 22;270(5244):1992-4
pubmed: 8533091
J Neurosci. 2003 Oct 1;23(26):8867-71
pubmed: 14523088
Blood Coagul Fibrinolysis. 1994 Apr;5(2):167-71
pubmed: 8054448
Front Neurosci. 2015 Nov 04;9:423
pubmed: 26582973
J Cell Physiol. 1995 Dec;165(3):647-57
pubmed: 7593245
J Neurosci. 2020 Jul 1;40(27):5161-5176
pubmed: 32444385
Cell Mol Life Sci. 1999 Oct 1;56(1-2):104-32
pubmed: 11213252
Front Cell Neurosci. 2015 Oct 16;9:415
pubmed: 26528141
J Clin Invest. 2010 Jun;120(6):2194-205
pubmed: 20440070
Semin Thromb Hemost. 2002 Dec;28(6):545-54
pubmed: 12536348
Neurol Res. 2017 Oct;39(10):862-868
pubmed: 28738762
CNS Neurosci Ther. 2019 Mar;25(3):303-313
pubmed: 30403004
Front Neurosci. 2019 Feb 08;13:43
pubmed: 30800052
J Clin Invest. 1991 Oct;88(4):1067-72
pubmed: 1833420
Front Mol Neurosci. 2017 Sep 15;10:294
pubmed: 28966576
Neurobiol Aging. 2011 Jun;32(6):1079-89
pubmed: 19604604
Neural Regen Res. 2016 Feb;11(2):212-3
pubmed: 27073359
J Cereb Blood Flow Metab. 2018 Nov;38(11):1896-1910
pubmed: 29547062
Neural Plast. 2020 Sep 1;2020:2960343
pubmed: 32952546
Am J Pathol. 1999 Dec;155(6):1901-13
pubmed: 10595921
Neural Regen Res. 2018 Apr;13(4):616-623
pubmed: 29722304
Nature. 2018 Jul;559(7715):S4-S7
pubmed: 30046080
Nat Rev Neurosci. 2017 May;18(5):281-298
pubmed: 28360418
Acta Pharmacol Sin. 2017 Sep;38(9):1205-1235
pubmed: 28713158
Nat Commun. 2019 Mar 13;10(1):1193
pubmed: 30867420
Brain Res. 2015 Dec 10;1629:1-9
pubmed: 26453830
Nat Rev Neurol. 2017 Aug;13(8):457-476
pubmed: 28708131
Trends Neurosci. 2017 Jun;40(6):347-357
pubmed: 28494972
Brain Res. 2010 Oct 8;1355:7-15
pubmed: 20709033
Front Cell Neurosci. 2015 Aug 17;9:304
pubmed: 26347605
Front Cell Neurosci. 2015 May 26;9:191
pubmed: 26074767
Nat Neurosci. 2010 Jul;13(7):812-8
pubmed: 20581818
Neuron. 2003 Mar 27;37(6):925-37
pubmed: 12670422
Neurodegener Dis. 2004;1(4-5):205-12
pubmed: 16908991
Nature. 1993 Feb 4;361(6411):453-7
pubmed: 8429885
J Neurochem. 2020 Feb;152(4):468-481
pubmed: 31602645
J Biol Chem. 2003 May 23;278(21):19054-61
pubmed: 12754271
Front Cell Neurosci. 2019 Apr 24;13:164
pubmed: 31105531
Lancet. 2002 Jun 29;359(9325):2242-7
pubmed: 12103288
Cell. 2019 Oct 3;179(2):312-339
pubmed: 31564456
Cell Physiol Biochem. 2016;38(4):1472-82
pubmed: 27035834
Nature. 2000 Oct 19;407(6806):923-6
pubmed: 11057674
J Neurochem. 2000 Nov;75(5):2172-7
pubmed: 11032907
Exp Mol Med. 2020 Mar;52(3):367-379
pubmed: 32152451
J Cereb Blood Flow Metab. 2019 Nov;39(11):2157-2171
pubmed: 29890880
J Neurosci. 1997 Dec 1;17(23):8984-96
pubmed: 9364046
J Neurosci. 2020 May 20;40(21):4251-4263
pubmed: 32332118
Nature. 1999 Sep 23;401(6751):376-9
pubmed: 10517635
Brain. 2020 Sep 1;143(9):2844-2857
pubmed: 32830216
J Neurochem. 2009 Apr;109(2):303-15
pubmed: 19222708
J Neurosci. 2003 Aug 13;23(19):7368-75
pubmed: 12917371
J Biol Chem. 1997 Dec 26;272(52):33062-7
pubmed: 9407089
Nat Neurosci. 1998 May;1(1):47-53
pubmed: 10195108
Nat Neurosci. 2003 Feb;6(2):168-74
pubmed: 12524546
Mol Neurodegener. 2019 Aug 2;14(1):32
pubmed: 31375134
Cardiovasc Res. 2005 May 1;66(2):276-85
pubmed: 15820196
EMBO J. 2005 May 4;24(9):1706-16
pubmed: 15861134
Front Oncol. 2018 Feb 12;8:24
pubmed: 29484286
Front Mol Neurosci. 2020 Aug 04;13:137
pubmed: 32848600
J Biol Chem. 2018 Jun 15;293(24):9234-9247
pubmed: 29720403
J Neurosci Res. 2002 Oct 15;70(2):249-55
pubmed: 12271474

Auteurs

Manuel Yepes (M)

Department of Neurology, Emory University School of Medicine; Department of Neurology, Veterans Affairs Medical Center; Division of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, Atlanta, GA, USA.

Classifications MeSH